
Articles
-
2 weeks ago |
healio.com | Regina Schaffer
Read more Key takeaways: Compared with methotrexate, systemic therapies for psoriasis either reduced or slightly increased cardiovascular risk. Patients with psoriasis should receive a cardiovascular risk assessment before treatment. Various systemic therapies for psoriasis either reduced, slightly increased or had no effect on risk for major adverse cardiovascular events, highlighting the need to perform a cardiovascular risk assessment before initiating any treatment.
-
3 weeks ago |
healio.com | Regina Schaffer
Key takeaways: The National Psoriasis Foundation Commit to Cure Gala is raising funds to support psoriatic disease research. This year’s honorees include Joel M. Gelfand, MD. The National Psoriasis Foundation will host its annual Commit to Cure gala on June 18, the organization’s largest fundraiser that draws members of the psoriatic disease community from around the country. The gala will take place at Cipriani 42nd Street in New York City.
-
1 month ago |
healio.com | Regina Schaffer
Key takeaways: Systemic control of inflammation with upadacitinib may reduce cardiovascular event risk in adults with atopic dermatitis. Treated adults with AD had fewer heart events compared with real-world populations. Adults with atopic dermatitis treated with upadacitinib had fewer major adverse cardiovascular events compared with background rates in real-world populations, adding to research supporting the drug’s potential cardioprotective benefits.
-
1 month ago |
healio.com | Regina Schaffer
Key takeaways:Research suggests the impact of pregnancy on melanoma risk remains unclear. Any observed changes in melanocytic nevi during pregnancy should be considered suspicious unless proven otherwise. Alterations in the size and number of moles are commonly reported among the many changes taking place during pregnancy; however, what such changes might mean when it comes to melanoma risk remains an open question.
-
1 month ago |
healio.com | Regina Schaffer
Key takeaways:A wearable electrical stimulation device improved hair density and thickness for men with androgenic alopecia. The device was safe and well tolerated. In a small pilot study, men with androgenic alopecia saw improvements in hair density and thickness after 6 months of daily, 30-minute treatments with a wearable, low-level electrical stimulation device, researchers reported.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →